Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2)
oleh: Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Lei Yang, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Yuxian Bai, Wei Li, Yiping Zhang, Guanghai Dai, Dong Ma, Jingdong Zhang, Chunmei Bai, Yunchao Huang, Wangjun Liao, Lin Wu, Xi Chen, Yan Yang, Junye Wang, Shoujian Ji, Hui Zhou, Yan Wang, Zhuo Ma, Yanqi Wang, Bo Peng, Jiya Sun, Christoph Mancao
| Format: | Article |
|---|---|
| Diterbitkan: | Nature Portfolio 2022-02-01 |
Deskripsi
Patients with advanced esophageal cancer have poor prognosis and limited treatment options. This randomized, phase II trial compares the efficacy and safety of the anti-PD-1 antibody sintilimab versus chemotherapy in Chinese patients with esophageal squamous cell carcinoma after first-line therapy